The phase I clinical administration of the humanized monoclonal antibody injection MG-ZG122 developed by Mabgeek Biotech has been completed.

Shanghai Mabgeek Biotech Co., Ltd. (hereinafter referred to as " Mabgeek Biotech ") is an innovative drug research and development company in the clinical stage. The company announced that its independently developed Class 1 innovative drug MG-ZG122 humanized monoclonal antibody injection (hereinafter referred to as "MG-ZG122") has been width: 100%; background-color: rgb(255, 255, 255); box-sizing: border-box !important; overflow-wrap: break-word !important;">May 25, 2023 The single-dose Phase I clinical trial of healthy subjects was completed and all cohorts of subjects were dosed with good safety.

) and other diseases.

The prevalence of asthma in people aged and over is4.2 %, the total is4 5.7 million^[1]. At present, the overall control level of asthma in my country is still not ideal. The overall asthma control rate in urban areas of 30 provinces and cities in my country is only 28.5%^[2]. The rate of uncontrolled severe asthma reached 44%, occupying most of the medical resources and medical expenses of asthma patients. -sizing: border-box !important; overflow-wrap: break-word !important; letter-spacing: normal; font-family: "Helvetica Neue", sans-serif; font-size: 12px;">^[3] .

Studies have shown that asthma is a heterogeneous disease, and multiple inflammatory pathways are involved in the pathogenesis of asthma. Among them, type 2 (Th2) inflammation-driven asthma is the most common, with two-thirds of asthma patients having Th2 asthma, which is typically characterized by elevated levels of type 2 inflammatory biomarkers, including type 2 cytokines (IL-4, IL-5 and IL-13), eosinophils, serum IgE, and exhaled nitric oxide (Fractional exhaled Nitric Oxide, FeNO). However, approximately one-third of patients with asthma do not show an increase in Th2 inflammatory markers.

Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine. It plays a key role in the development and persistence of airway inflammation. TSLP can drive downstream Th2 cell polarization and the release of Th2-type inflammatory factors, leading to inflammatory symptoms : border-box !important; overflow-wrap: break-word !important; letter-spacing: normal; font-family: "Helvetica Neue", sans-serif; font-size: 12px;">^[4]. At the same time, it can also Activates multiple types of inflammatory cells (such as mast cells, basophils, neutrophils, etc.), thereby playing a role in non-Th2 driven inflammation^[5]. TSLP is active upstream of the inflammatory cascade and has been proven in clinical trials to be an effective therapeutic target in inflammatory diseases such as asthma. ^[6]. Currently, only one TSLP targeted drug has been approved worldwide, namely Tezepelumab from Amgen/AstraZeneca^{[7 ,8]}, it is the only biologic without phenotypic (such as eosinophilic or allergic) or biomarker limitations for the treatment of severe asthma.